Abstract
Only limited evidence exists on the therapeutic potential of biologic agents in the treatment of myositis. We present a brief review of the literature on off-label experiences of biologic agents in myositis, with a special interest in abatacept. Rituximab has been indicated to be beneficial and well tolerated in one large randomized controlled trial and many smaller studies. Initial data on tumour necrosis factor (TNF) inhibitors are conflicting. There are only a few case reports and mechanistic studies on the treatment of myositis with other biologics, including alemtuzumab, anakinra, tocilizumab and abatacept. We report a patient with severe myositis overlap syndrome, manifesting also as rheumatoid arthritis, peripheral vasculitis and interstitial lung disease. Her myositis was refractory to many conventional and biologic therapies but was well controlled with abatacept. This suggests that abatacept might be a beneficial option for the treatment of refractory myositis and that clinical trials are needed to further investigate its efficacy.
Similar content being viewed by others
References
Aggarwal R, Oddis CV (2012) Therapeutic advances in myositis. Curr Opin Rheumatol 24:635–641
Carstens PO, Schmidt J (2013) Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol.
Gordon PA, Winer JB, Hoogendijk JE, Choy EH (2012) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 8:CD003643
Couderc M, Gottenberg JE, Mariette X et al (2011) Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology (Oxford) 50:2283–2289
Majmudar S, Hall HA, Zimmermann B (2009) Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol 15:338–340
Garcia-Hernandez FJ, Gonzalez-Leon R, Castillo-Palma MJ, Sanchez-Roman J (2011) Rituximab is effective in the treatment of patients with idiopathic inflammatory myopathy. Clin Exp Rheumatol 29:363–364
Basnayake C, Cash K, Blumbergs P, Limaye V (2013) Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series. Clin Rheumatol.
Munoz-Beamud F, Isenberg DA (2013) Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol 31:896–903
Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314–324
Muscle Study Group (2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70:427–436
Efthimiou P, Schwartzman S, Kagen LJ (2006) Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 65:1233–1236
Anandacoomarasamy A, Howe G, Manolios N (2005) Advanced refractory polymyositis responding to infliximab. Rheumatology (Oxford) 44:562–563
Hengstman GJ, van den Hoogen FH, Barrera P et al (2003) Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 50:10–15
Dastmalchi M, Grundtman C, Alexanderson H et al (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67:1670–1677
Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G (2006) Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33:1802–1804
Lazarou IN, Guerne PA (2013) Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol 40:550–564
Dalakas MC, Rakocevic G, Schmidt J et al (2009) Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132:1536–1544
Zong M, Dorph C, Dastmalchi M et al. (2013) Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis.
Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H (2009) Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 60:2505–2512
Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T (2011) Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 50:1344–1346
Higgs BW, Zhu W, Morehouse C et al (2014) A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 73:256–262
Iannone F, Lapadula G (2012) The inhibitor of costimulation of T cells: abatacept. J Rheumatol Suppl 89:100–102
Musuruana JL, Cavallasca JA (2011) Abatacept for treatment of refractory polymyositis. Joint Bone Spine 78:431–432
Arabshahi B, Silverman RA, Jones OY, Rider LG (2012) Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 160:520–522
Murata K, Dalakas MC (1999) Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 155:453–460
Nagaraju K, Raben N, Villalba ML et al (1999) Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 92:161–169
the U.S. National Institutes of Health: ClinicalTrials.gov. Available at: www.clinicaltrials.gov. Accessed 23 Dec 2013
Disclosures
MK has attended several rheumatologic congresses and meetings by sponsorship from AbbVie, BMS, Pfizer, MSD, Roche and UCB. MK is a member of the advisory boards of AbbVie, BMS, Pfizer, MSD, Roche and UCB. AK has no disclosures.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kerola, A.M., Kauppi, M.J. Abatacept as a successful therapy for myositis—a case-based review. Clin Rheumatol 34, 609–612 (2015). https://doi.org/10.1007/s10067-014-2507-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-014-2507-4